Dicer, Drosha, and outcomes in patients with ovarian cancer

New England Journal of Medicine

Volumn 359, Issue 25, 2008, Pages 2641-2650

  Merritt, William M ^a   Lin, Yvonne G ^a   Han, Liz Y ^a   Kamat, Aparna A ^a   Spannuth, Whitney A ^a   Schmandt, Rosemarie ^a   Urbauer, Diana ^a   Pennacchio, Len A ^b,c   Cheng, Jan Fang ^b,c   Nick, Alpa M ^a   Deavers, Michael T ^a   Mourad Zeidan, Alexandra ^a   Wang, Hua ^a   Mueller, Peter ^a   Lenburg, Marc E ^d   Gray, Joe W ^b   Mok, Samuel ^e   Birrer, Michael J ^f   Lopez Berestein, Gabriel ^a   Coleman, Robert L ^a   Bar Eli, Menashe ^a   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c DOE JOINT GENOME INSTITUTE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; DROSHA ENZYME; GENOMIC DNA; MESSENGER RNA; RIBONUCLEASE III; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 58049213696     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0803785     Document Type: Article

References (41)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
2. Halder J, Kamat AA, Landen CN Jr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006;12:4916-24.
3. Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
4. Hannon GJ. RNA interference. Nature 2002;418:244-51.
5. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-9.
6. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6.
7. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 2006;17:189-202.
8. Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 2007;210:279-89.
9. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
10. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7.
11. McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003;13:253-8.
12. Zhang L, Coukos G. MicroRNAs: a new insight into cancer genome. Cell Cycle 2006;5:2216-9.
13. Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006;103:9136-41.
14. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001;158:1279-88.
15. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
17. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-21.
18. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:325-33.
19. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
20. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
21. Pawitan Y, Bjöhle J, Amler L, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7:R953-R964.
22. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301.
23. Ahituv N, Kavaslar N, Schackwitz W, et al. Medical sequencing at the extremes of human body mass. Am J Hum Genet 2007;80:779-91.
24. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8957-61.
25. The R Foundation for Statistical Computing. R: a language and environment for statistical computing. Vienna: The R Foundation, 2007. (Accessed November 24, 2008, at http://www.R-project.org.)
26. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003;35:215-7. [Erratum, Nat Genet 2008;35:287.]
27. Cobb BS, Hertweck A, Smith J, et al. A role for Dicer in immune regulation. J Exp Med 2006;203:2519-27.
28. Damiani D, Alexander JJ, O'Rourke JR, et al. Dicer inactivation leads to progressive functional and structural degeneration of the mouse retina. J Neurosci 2008;28:4878-87.
29. Kobayashi T, Lu J, Cobb BS, et al. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci U S A 2008;105:1949-54.
30. Karube Y, Tanaka H, Osada H, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-5.
31. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007;67:2345-50.
32. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of Dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006;169:1812-20.
33. Sugito N, Ishiguro H, Kuwabara Y, et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 2006;12:7322-8.
34. Qi HH, Ongusaha PP, Myllyharju J, et al. Prolyl 4-hydroxylation regulates Argonaute 2 stability. Nature 2008;455:421-4.
35. Schmitter D, Filkowski J, Sewer A, et al. Effects of Dicer and Argonaute downregulation on mRNA levels in human HEK293 cells. Nucleic Acids Res 2006;34:4801-15.
36. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-6.
37. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer 2007;43:1529-44.
38. Chiosea SI, Barnes EL, Lai SY, et al. Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of Dicer expression. Virchows Arch 2008;452:629-35.
39. Welker NC, Habig JW, Bass BL. Genes misregulated in C. elegans deficient in Dicer, RDE-4, or RDE-1 are enriched for innate immunity genes. RNA 2007;13:1090-102.
40. Irvin-Wilson CV, Chaudhuri G. Alternative initiation and splicing in dicer gene expression in human breast cells. Breast Cancer Res 2005;7:R563-R569.
41. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-41.